MX9301387A - Metodo y composicion para el tratamiento de osteoporosis. - Google Patents

Metodo y composicion para el tratamiento de osteoporosis.

Info

Publication number
MX9301387A
MX9301387A MX9301387A MX9301387A MX9301387A MX 9301387 A MX9301387 A MX 9301387A MX 9301387 A MX9301387 A MX 9301387A MX 9301387 A MX9301387 A MX 9301387A MX 9301387 A MX9301387 A MX 9301387A
Authority
MX
Mexico
Prior art keywords
treatment
osteoporosis
composition
mammal
prevention
Prior art date
Application number
MX9301387A
Other languages
English (en)
Spanish (es)
Inventor
Hans-Peter Guler
Satish Bhatia
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of MX9301387A publication Critical patent/MX9301387A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX9301387A 1992-03-13 1993-03-12 Metodo y composicion para el tratamiento de osteoporosis. MX9301387A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85054592A 1992-03-13 1992-03-13

Publications (1)

Publication Number Publication Date
MX9301387A true MX9301387A (es) 1994-08-31

Family

ID=25308435

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9301387A MX9301387A (es) 1992-03-13 1993-03-12 Metodo y composicion para el tratamiento de osteoporosis.

Country Status (11)

Country Link
US (2) US6300309B1 (enExample)
EP (1) EP0560723A1 (enExample)
JP (1) JP3771280B2 (enExample)
KR (1) KR930019223A (enExample)
AU (1) AU666514B2 (enExample)
CA (1) CA2091534A1 (enExample)
IL (1) IL104940A0 (enExample)
MX (1) MX9301387A (enExample)
NZ (1) NZ247123A (enExample)
TW (1) TW267102B (enExample)
ZA (1) ZA931778B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728676A (en) * 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
JPH10504971A (ja) * 1994-09-08 1998-05-19 カイロン コーポレイション インスリン様増殖因子の改善された生産方法
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US20030069177A1 (en) 2000-05-16 2003-04-10 Genentech, Inc. Method for treating cartilage disorders
CA2356109C (en) 1999-01-06 2008-04-22 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
DK1265630T3 (da) 2000-03-24 2006-10-09 Genentech Inc Anvendelse af insulin til behandling af brusksygdomme
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
WO2006130769A2 (en) 2005-06-02 2006-12-07 Tercica, Inc. Methods for treatment of growth disorders
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
WO2007093220A1 (en) * 2006-02-17 2007-08-23 Associazione Foresta Per La Ricerca Nella Riproduzione Umana Use of insulin-like factor 3 for treating osteoporosis and bone disorders
US20080200425A1 (en) * 2007-02-16 2008-08-21 Kurtz Seymour J Methods and compositions for regulating bone mineral density
CA3059593A1 (en) * 2017-05-21 2018-11-29 Igf Oncology, Llc An insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68218A (en) * 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
DE3486216T2 (de) 1983-04-25 1994-02-17 Chiron Corp Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren.
CA1322714C (en) * 1986-11-14 1993-10-05 Harry N. Antoniades Wound healing and bone regeneration
DE3851776T2 (de) 1987-04-28 1995-05-04 Boehringer Mannheim Gmbh Verwendung von IGF-II zur Behandlung von Knochenkrankheiten.
EP0318184A1 (en) 1987-11-12 1989-05-31 Schering Corporation Acceleration of bone formation with GM-CSF
ZA9010332B (en) 1989-12-22 1991-08-28 Ciba Geigy Method of reducing or preventing adverse effect of steroid therapy and compositions therefor
NZ236618A (en) * 1990-01-03 1997-06-24 Ciba Geigy Ag Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound
JPH0818999B2 (ja) * 1990-01-05 1996-02-28 藤沢薬品工業株式会社 インシュリン様成長因子ｉの乾燥製剤
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation

Also Published As

Publication number Publication date
US6300309B1 (en) 2001-10-09
NZ247123A (en) 1997-08-22
KR930019223A (ko) 1993-10-18
AU666514B2 (en) 1996-02-15
AU3406893A (en) 1993-09-16
EP0560723A1 (en) 1993-09-15
JP3771280B2 (ja) 2006-04-26
TW267102B (enExample) 1996-01-01
JPH069429A (ja) 1994-01-18
IL104940A0 (en) 1993-07-08
CA2091534A1 (en) 1993-09-14
US6358925B1 (en) 2002-03-19
ZA931778B (en) 1993-09-13

Similar Documents

Publication Publication Date Title
ES2156839T1 (es) Medicamento que contiene alginato e implante para tratar la fibrosis.
MX9304435A (es) Compuesto y composicion farmaceutica para el tratamiento y la profilaxis de la obesidad o para el tratamiento de la diabetes del tipo ii.
ATE112684T1 (de) Verwendung von igf-ii zur behandlung von knochenkrankheiten.
LV12284A (lv) No kudras izdaliti bioaktivi produkti un tos saturosas farmaceitiskas un kosmetiskas kompozicijas
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
DE68919358D1 (de) Zusammensetzung zur behandlung der schizophrenie.
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
MX9303554A (es) Peptido similar al glucagon y derivados de insulinotropina.
DE69533112T2 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
MX9703609A (es) Uso de fragmentos de angiotensina ii y analogos de la misma para la preparacion de composiciones en la preparacion de tejido.
RU94046291A (ru) Способ профилактики и лечения периферической невропатии, композиция, содержащая инсулин-подобный фактор роста i
MD1558F2 (en) Method of prophylaxis of mammal acute renal insufficiency utilizing IGF-I insulin-like growth factor
ES2151083T3 (es) Composiciones orales que contienen ondansetron.
RU94002337A (ru) Фармацевтическая композиция, применение гамма-линоленовой или дигомо-гамма-линоленовой кислоты для лечения поражений после облучения, способ лечения
MX9710252A (es) Utilizacion de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento.
RU93058532A (ru) Фармацевтическая композиция для остеоиндукции, способ генерации новой кости
DE69316013D1 (de) Verwendung von phosphinate zur behandlung der osteoporose
KR930019223A (ko) 골다공증의 치료를 위한 방법 및 조성물
NO934381L (no) Terapeutiske sammensetninger for osteoinduksjon
CA2156481A1 (en) 5-ht2 receptor antagonist compositions useful in treating venous conditions
UY26514A1 (es) " composición para el tratamiento de tejidos danados".
ES2078175A1 (es) Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones.
ES2147796T3 (es) Composicion para el tratamiento o la prevencion del herpes.
SE8403659D0 (sv) Synergistic pharmaceutical composition
CO5031290A1 (es) Formulacion lo